Probiotics Evidence 2026: Oral, Mental Health, and Surgical Recovery

All4Nutra had a look in the editions between April till July 2026 of the “The Vitamin Professor Newsletter editions” where three probiotic trials are analyzed.

They cover gingivitis management, depression and sexual function in men on SSRI treatment, and clinical recovery after gastric cancer surgery. A fourth edition places probiotics among the ingredient categories affected by the renaming of PCOS to PMOS. Each passage below is reproduced verbatim from the newsletter, as written by Dr. Gene Bruno, DBM, MS, RH(AHG) [1][2][3][4].

Probiotics were the second most frequent subject of the named newsletter over this period, after vitamin D. The three trials sit in unrelated therapeutic areas, which is what makes the set useful: it shows the category being tested well outside the digestive-health positioning that dominates commercial probiotic formats. All4Nutra has covered the underlying mechanisms of action and health benefits of probiotics in a separate review.

The text inside each quotation is the newsletter’s own wording. Citation markers within the quotations have been renumbered to this article’s source list, Latin binomials are set in italics as in the original, and nothing else inside them has been altered.

First trial: Weissella cibaria CMU for gingivitis

From The Vitamin Professor Newsletter, July 20, 2026, section “Weissella cibaria for managing gingivitis” [1]:

In this randomized, double-blind, placebo-controlled trial [5], 80 participants received either Weissella cibaria CMU (OraCMU) tablets (2.0 × 108 CFU/g; n = 40) or placebo (n = 40) twice daily for 8 weeks. The primary outcome was the gingival index (GI), and secondary outcomes included bleeding on probing (BOP), probing depth, clinical attachment level, gingival recession, plaque index, inflammation-related proteins, and oral microbiota. Clinical parameters were assessed at six preselected index teeth (#16, 12, 24, 32, 36, and 44). At week 8, the probiotic group showed significantly greater reductions in GI (-0.19 ± 0.03 vs. -0.08 ± 0.04; P = .035) and BOP (-7.74 ± 1.54 vs. -2.82 ± 1.60; P = .030) compared with the placebo group. Inflammatory markers, including fibroblast growth factor-5 (P = .003), thymic stromal lymphopoietin (P = .017), and the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio (P = .021), were significantly decreased. The levels of Porphyromonas gingivalis (P = .001), Treponema denticola (P = .005), and Prevotella intermedia (P = .046) were also significantly reduced, while Weissella increased (P < .001) in the probiotic group. Eight-week supplementation with OraCMU improved gingival health and modulated the oral microbiota and inflammatory response. No serious adverse events were reported during the study period. These findings support the potential clinical utility of OraCMU as a probiotic adjunct for managing gingivitis.

Editorial note: the newsletter renders the cell count as “2.0 × 108 CFU/g”, which appears to have lost its exponent formatting in publication. Verify the figure against the cited trial [5]. Oral-delivery probiotic formats have been covered separately on the portal in a professional evaluation of an oral probiotic supplement.

Second Trial: Lactofem alongside SSRI treatment for depression and sexual function in men

From The Vitamin Professor Newsletter, May 6, 2026, section “Probiotic for reducing depression and enhancing sexual function in men” [3]:

A randomized controlled trial [6] was conducted to determine the effect of the probiotic Lactofem (undisclosed Lactobacillus strains) combined with Escitalopram (an SSRI medication) on severity of depression and sexual function in 240 men diagnosed with mild to moderate depression undergoing SSRI treatment. The intervention group (n=119) received Lactofem alongside Escitalopram, while the control group (n=121) received only Escitalopram for 2 months. Depression severity was measured by the Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI). Sexual function was assessed using the International Index of Erectile Function (IIEF) questionnaire at baseline and after treatment. Results were that both groups showed significant improvement in depression scores (P < 0.05). The Lactofem group had a greater reduction in HDRS (6.42 ± 3.45 vs 8.61 ± 4.15, P < 0.05) and BDI scores (27.63 ± 4.13 vs 30.24 ± 4.51, P < .05). Sexual function improvements were significantly higher in the intervention group across all domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction (all P < 0.05). In conclusion, adding Lactofem to Escitalopram treatment significantly reduces depression severity and enhances sexual function in men with mild to moderate depression.

Third Trial: Probiotics and clinical recovery after gastrectomy

From The Vitamin Professor Newsletter, April 21, 2026, section “Probiotics for clinical outcomes in gastric cancer surgery” [4]:

A single-centered, prospective, double blinded, placebo-controlled trial [7] aimed to evaluate the effect of probiotics on the length of hospital stay, other post-operative clinical outcomes, nutritional status, inflammatory and immune markers in patients undergoing gastrectomy for gastric cancer. Participants were randomized to receive probiotics or placebo for 10 days starting on postoperative day (POD) 1. Blood samples were collected preoperatively and POD 10 to assess hemoglobin, total counts, albumin, IL6, TNFα, and IgA. Clinical outcomes including time to first flatus, first passage of stools, oral diet resumption and length of hospital stay (LOHS). Results were that, of 42 participants (22 probiotic, 20 placebo), baseline characteristics were comparable. The probiotic group had a significantly shorter median LOHS (9 vs. 12 days, p<0.05), earlier time to first passage of flatus (2.6 vs. 4.3 days, p<0.05), earlier time to first passage of stools (3.6 vs. 5.7 days, p<0.05), and oral diet resumption (3.6 vs. 5.7 days, p<0.05). No significant differences were observed in inflammatory markers (TLC, IL-6, TNF-α), immune markers (IgA), nutritional status (albumin, hemoglobin), or postoperative complications (p>0.05). In conclusion, postoperative probiotic supplementation reduced LOHS and improved gastrointestinal recovery in GC patients undergoing gastrectomy, but did not significantly affect inflammatory, immune, or nutritional markers.

Probiotics among the ingredient categories affected by the PMOS rename

The May 18, 2026 special edition of the Vitamin Professor newsletter addressed the renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). It is commentary rather than a trial report, and probiotics appear in it as one item in a list of ingredient categories. From the section “The Impact on the Dietary Supplement Industry” [2]:

The renaming of PCOS to PMOS has the potential to significantly impact the dietary supplement industry since it reframes the condition from a primarily reproductive disorder to a broader metabolic and endocrine health condition. Essentially, this shift is likely to expand consumer demand beyond fertility-focused products toward supplements targeting insulin resistance, metabolic health, inflammation, weight management, cardiovascular health, mood, and hormonal balance. McEvoy from Nutritional Outlook [8] has already noted that the PMOS terminology validates a more “whole-body” therapeutic approach, potentially broadening product development opportunities for ingredients such as myo-inositol, berberine, omega-3 fatty acids, magnesium, CoQ10, vitamin D, probiotics, adaptogenic botanicals, and glucose-support formulas.

What the strain reporting means for formulators

The three trials differ sharply in how precisely the tested product is identified, which determines how far each result can be carried into a specific formulation.

The gingivitis trial names the organism, the designation, and the commercial name: Weissella cibaria CMU (OraCMU), with a stated cell count, a tablet format, and twice-daily dosing over 8 weeks.
The depression trial names the product, Lactofem, but the newsletter states its Lactobacillus strains are undisclosed.
The gastrectomy trial reports the intervention only as “probiotics”, with no strain, dose, or composition given in the newsletter summary.

Only the first of the three supports a strain-level read-across. The other two describe an effect observed with a product whose composition is either withheld or not stated in the summary, which is the ordinary limit of probiotic evidence rather than a flaw in these particular reports.

Format and viability sit downstream of that choice. The portal has covered the selection of lyoprotectants for stabilizing a freeze-dried probiotic, microencapsulation of Bifidobacterium longum by spray-drying, and encapsulation and functional activity of Lactobacillus reuteri strains. Where live-cell viability is the constraint, the portal’s guide to postbiotics sets out the non-viable alternative and where the evidence for it currently stands.

About the source publication

The Vitamin Professor Newsletter is published on LinkedIn by Dr. Gene Bruno, DBM, MS, RH(AHG), who states he is a 47-year veteran of the dietary supplement industry, served for 20 of those years as Professor of Nutraceutical Science at Huntington University of Health Sciences, and now serves as Chief Scientific Officer for Nutraland USA. The newsletter is free and published bimonthly, and covers recent research on nutraceuticals.

Alongside the newsletter, Dr. Bruno hosts The Vitamin Professor podcast, which explores the supplement space with industry professionals and focuses on nutraceutical science. Episodes are available on YouTube, Spotify, Apple Podcasts, iHeart, and other podcast platforms. Notifications of new episodes are distributed by email through Vitamin Retailer Industry Partner Offers and Announcements.

These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.

Sources

Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, July 20, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–61b8c
Primary source (original publication): Bruno G. “SPECIAL EDITION OF THE VITAMIN PROFESSOR™ NEWSLETTER: The Renaming of PCOS to PMOS, and the Impact on the Dietary Supplement Industry,” LinkedIn newsletter, May 18, 2026. https://www.linkedin.com/pulse/special-edition-vitamin-professor-newsletter-renaming-dr-gene-ln1ec
Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, May 6, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–w0qpe
Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, April 21, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–tfp1e
Jeon HW, Yang KI, Yu SJ, Kang MS, Lee WP. Clinical Efficacy of the Probiotic Weissella cibaria CMU in Adults with Gingivitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Med Food. 2026 Jun;29(6):319-331. doi: 10.1177/1096620X261430298.
Taghavi SA, Sadri M, Hashemimohammadabad M, Hashemimohammadabad N, Hashemimohammadabad Z, Bazarganipour F. Adjuvant administration probiotic effects on sexual function in depressant men undergoing selective serotonin reuptake inhibitor treatment: a double-blinded randomized controlled trial. J Sex Med. 2026 Apr 9;23(5):qdag043. doi: 10.1093/jsxmed/qdag043.
Pal D, Anandhi A, Keerthi AR, Nanda N, Kate V. Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial. J Gastrointest Cancer. 2026 Apr 17;57(1):93. doi: 10.1007/s12029-026-01449-3. PMID: 41996041.
McEvoy E. Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS). Nutritional Outlook. May 13, 2026. https://www.nutritionaloutlook.com/view/global-consensus-renames-pcos-to-polyendocrine-metabolic-ovarian-syndrome-pmos